Partnerships for Advancing Development of Diagnostics for Infectious Diseases

Source-based overview

The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting partnerships between academic (or small business) investigators and one or more industrial partner(s) for translational development of a diagnostic test that has demonstrated proof-of-concept. Novel diagnostics are needed to implement treatment strategies, evaluate vaccines and identify infectious disease outbreaks, but too often, early diagnostic breakthroughs are not being translated into successful commercial products. Investigators often develop promising diagnostics but then face barriers when navigating the process towards commercialization. The goal is to align investigators with experienced industry partners early in the development process, to enable early de-risking and ensure that the end-product will be fit for purpose. A science advisory board together with NIAID oversight will help maintain the focus of projects. Annual meetings and workshops will foster collaborations and knowledge exchange with biotech/industry developers, and other investigators in the early diagnostic space. This partnership concept aligns with NIH’s mission to support the translation of the most promising diagnostic technologies to better treat and prevent infectious diseases. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. The official record contains the controlling eligibility, budget, attachment and submission requirements for opportunity RFA-AI-28-017.

Eligibility

Eligible applicant types listed by the agency: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; City or township governments; State governments; Native American tribal governments (Federally recognized); County governments; Small businesses; Public and State controlled institutions of higher education; Private institutions of higher education; Special district governments; For profit organizations other than small businesses; Native American tribal organizations (other than Federally recognized tribal governments); Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; Others (see text field entitled "Additional Information on Eligibility" for clarification). Applicants must also satisfy every programme-specific condition in the official notice.

Funding and benefits

Estimated programme funding: USD 10,000,000

Expected number of awards: 10

Themes and supported activities

The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting partnerships between academic (or small business) investigators and one or more industrial partner(s) for translational development of a diagnostic test that has demonstrated proof-of-concept. Novel diagnostics are needed to implement treatment strategies, evaluate vaccines and identify infectious disease outbreaks, but too often, early diagnostic breakthroughs are not being translated into successful commercial products. Investigators often develop promising diagnostics but then face barriers when navigating the process towards commercialization. The goal is to align investigators with experienced industry partners early in the development process, to enable early de-risking and ensure that the end-product will be fit for purpose. A science advisory board together with NIAID oversight will help maintain the focus of projects. Annual meetings and workshops will foster collaborations and knowledge exchange with biotech/industry developers, and other investigators in the early diagnostic space. This partnership concept aligns with NIH’s mission to support the translation of the most promising diagnostic technologies to better treat and prevent infectious diseases. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.

Opportunity number: RFA-AI-28-017

Deadline and timeline

Forecast notice: deadline to be announced: Forecast notice: deadline to be announced.

Applicants should confirm the exact deadline time, time zone, required documents, portal steps and any institutional approvals on the official call page before submitting.

How to apply

Open the official Grants.gov record, review the full notice and attachments, and use the application package or agency route stated there.

Before applying, check eligibility rules, budgets, attachments, page limits, partner requirements, cost-share conditions and whether the opportunity uses an expression of interest, full proposal, registration or nomination stage.